Skip to main content
    G

    Genprex Inc (GNPX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.90
    -0.18 (-8.65%)

    Market Cap: $1.71M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Genprex Inc (GNPX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Genprex reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$16.23M, operating cash flow was -$15.31M and free cash flow was -$15.31M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.24M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $15.52M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$9.43M$10.54M$17.62M$11.51M$8.97M$7.30M$1.97M$971.43K$289.93K$354.88K
    Operating income-$15.52M-$21.17M-$31.06M-$23.83M-$20.67M-$17.96M-$10.68M-$12.36M-$3.31M-$4.13M
    Net income-$16.23M-$21.11M-$30.86M-$23.74M-$20.66M-$17.94M-$10.65M-$12.37M-$3.31M-$4.13M
    EBITDAN/A-$21.17MN/A-$23.81M-$20.65M-$17.94M-$10.67M-$12.36M-$3.31M-$4.13M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0-$2.21K
    Gross profit$0$0$0N/A$0$0$0N/A$0$0$0-$2.21K
    Operating income-$4.27M-$4.48M-$4.49M-$3.52M-$3.35M-$4.68M-$3.97M-$4.34M-$4.32M-$6.52M-$6.00M-$5.97M
    Net income-$4.24M-$4.45M-$4.46M-$3.79M-$3.80M-$4.67M-$3.96M-$4.33M-$4.32M-$6.50M-$5.97M-$5.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $7.83M were 77.1% of total assets of $10.16M, against total liabilities of $2.20M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$10.16M$4.12M$10.67M$25.09M$42.86M$31.37M$3.53M$9.27M$1.26M$1.91M
    Current assets$8.36M$2.08M$7.53M$21.47M$39.14M$27.70M$2.98M$8.85M$193.57K$1.64M
    Cash and equivalents$7.83M$1.60M$6.74M$20.95M$38.63M$27.32M$2.00M$8.60M$161.25K$1.60M
    Total liabilities$2.20M$2.50M$3.25M$2.81M$1.59M$450.72K$510.68K$387.82K$830.96K$285.66K
    Short-term debtN/AN/AN/AN/AN/AN/A$74.43K$92.75K$201.89KN/A
    Shareholder equity$7.96M$1.62M$7.42M$22.27M$41.28M$30.92M$3.02M$8.88M$428.57K$1.62M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$17.52M$17.14M$20.31M$10.16M$3.56M$3.83M$6.01M$4.12M$3.91M$6.60M$12.56M$10.67M
    Total liabilities$3.80M$2.34M$3.38M$2.20M$2.79M$2.44M$2.14M$2.50M$2.24M$2.26M$3.81M$3.25M
    Cash and equivalents$15.35M$15.15M$18.05M$7.83M$1.10M$1.35M$3.47M$1.60M$1.49M$2.46M$8.22M$6.74M
    Shareholder equity$13.72M$14.80M$16.93M$7.96M$767.81K$1.39M$3.87M$1.62M$1.66M$4.35M$8.76M$7.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$15.31M-$17.92M-$24.74M-$17.62M-$14.28M-$13.94M-$6.92M-$6.85M-$2.17M-$1.25M
    Capital expenditures$1$0$71.38K$4$31.70K$17.56K$33.37K$22.43K$5.89K$4.98K
    Free cash flow-$15.31M-$17.92M-$24.81M-$17.62M-$14.32M-$13.95M-$6.95M-$6.87M-$2.18M-$1.25M
    Dividends paidN/A$277.12MN/AN/AN/AN/AN/AN/A$0N/A
    Investing cash flow$0$774.64K-$71.21K-$59.73K-$83.80K-$2.34M-$946.90K-$103.32K-$63.42K-$89.53K
    Financing cash flow$21.54M$12.01M$10.59M$6.43K$25.68M$41.59M$1.27M$15.39M$793.97K$2.71M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.94M-$5.14M-$3.14M-$4.10M-$3.19M-$3.86M-$4.16M-$3.87M-$2.19M-$6.57M-$5.30M-$4.96M
    Capital expendituresN/AN/A$3$10$2$5$5$0$16.99K$16.99K$16.99K$10.00K
    Free cash flowN/AN/A-$3.14M-$4.10M-$3.19M-$3.86M-$4.16M-$3.87M-$2.20M-$6.59M-$5.31M-$4.97M
    Last 12 quarters

    Frequently Asked Questions About GNPX

    What is Genprex's annual revenue?

    Genprex reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Genprex profitable?

    No. Genprex reported net income of -$16.23M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does GNPX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.31M minus capital expenditures of $1 produced free cash flow of -$15.31M.

    How much debt does Genprex have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $7.83M.